PDCD1 and neoplasm: In addition to the aforementioned regulatory pathways validated experimentally, researchers have analyzed the relationship between m6A methylation modification and the expression of immunotherapeutic targets, such as PD-1, PD-L1, CTLA4, TIGIT, and LAG3 by bioinformatics, revealing the important roles of m6A modification patterns in the anti-tumor immunotherapy strategy for various cancers.